[68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time?
PET/CT
[68Ga]Ga-DOTANOC
head pancreas
neuroendocrine tumors
uncinate process
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Jul 2022
21 Jul 2022
Historique:
received:
29
06
2022
revised:
18
07
2022
accepted:
19
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
[68Ga]Ga-DOTA-peptide uptake in the pancreatic head/uncinate process (UP) is a frequent PET/CT finding. Although mostly physiologic, it can represent a pitfall in PET/CT reading, especially when focal. An increased frequency of UP uptake has been reported in patients (pts) affected by diabetes mellitus (DM). The aim of the study is to describe the frequency of [68Ga]Ga-DOTANOC UP uptake to evaluate its variations over time and its possible correlation with DM. In September 2017, a monocentric prospective observational electronic archive was initiated at our center to collect clinical and imaging data of pts undergoing [68Ga]Ga-DOTANOC PET/CT. Among the pts enrolled in the first 6 months (Sept 2017 to Feb 2018), those presenting [68Ga]Ga-DOTANOC PET/CT uptake at UP level were included. Pts with UP lesions already documented on CT/MRI or those that underwent surgical excision of UP before PET/CT were excluded from the analysis. [68Ga]Ga-DOTANOC UP uptake was classified as diffuse or focal and compared with the pattern observed in previous PET/CT scans performed at our center. An increased frequency of UP uptake was also correlated with the presence of DM. In the first 6 months, 253 pts were enrolled in the archive and 172 out of them were included in the analysis. UP increased uptake was frequently observed (77/172, 44.8%) and was mostly diffuse (62/77). In 75/172 pts (43.6%), previous [68Ga]Ga-DOTANOC PET/CT scans were available (overall 268 scans; number of previous PET per pt range: 1-20) and were retrospectively reviewed. Despite the fact that, in most pts, the uptake pattern was stable over time (54/75 pts, 72%), it changed in approximately one third of cases (21/75, 28%). Among DM pts (29/172), only 10/29 (34.4%) presented increased UP uptake. UP [68Ga]Ga-DOTANOC uptake is a frequent non-malignant finding (slightly higher than previously reported), mostly presenting with a diffuse pattern. However, contrary to previous reports, our data show that the pattern of uptake may vary over time in approximately one third of the cases and it is not more frequently observed in pts with DM.
Identifiants
pubmed: 35884602
pii: cancers14143541
doi: 10.3390/cancers14143541
pmc: PMC9315701
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Nucl Med. 2007 Oct;48(10):1741-8
pubmed: 17873136
Clin Nucl Med. 2017 Jan;42(1):15-19
pubmed: 27775943
Q J Nucl Med Mol Imaging. 2010 Feb;54(1):61-7
pubmed: 20168287
Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):982-93
pubmed: 17225119
Pancreas. 2014 May;43(4):648-50
pubmed: 24713672
J Thorac Oncol. 2016 Aug;11(8):e99-e101
pubmed: 27079186
Pancreas. 2007 Nov;35(4):372-5
pubmed: 18090246
Clin Nucl Med. 2012 Jan;37(1):57-62
pubmed: 22157030
Eur J Nucl Med Mol Imaging. 2003 May;30(5):781-93
pubmed: 12707737
Clin Nucl Med. 2012 Apr;37(4):362-5
pubmed: 22391705
J Nucl Med. 2007 Apr;48(4):508-18
pubmed: 17401086
Metabolism. 1990 Sep;39(9 Suppl 2):78-81
pubmed: 2169575
Clin Transl Oncol. 2017 Jul;19(7):915-920
pubmed: 28144828
Nucl Med Mol Imaging. 2022 Feb;56(1):52-58
pubmed: 35186159
PLoS One. 2013;8(1):e55501
pubmed: 23383206
Diabetes. 1999 Jan;48(1):77-85
pubmed: 9892225
Clin Nucl Med. 2012 Nov;37(11):1052-7
pubmed: 22996234
Eur J Nucl Med Mol Imaging. 2010 May;37(5):1049-62
pubmed: 20306035
J Clin Gastroenterol. 2008 Jan;42(1):66-8
pubmed: 18097293
Nucl Med Commun. 2014 Jun;35(6):613-9
pubmed: 24686250
Curr Radiopharm. 2013 Mar;6(1):36-40
pubmed: 23470033
Cancer Res. 1987 Jan 15;47(2):551-8
pubmed: 3024822
Ann Nucl Med. 2018 Apr;32(3):191-196
pubmed: 29349562
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601
pubmed: 28547177
Medicine (Baltimore). 2020 May 29;99(22):e20197
pubmed: 32481385
J Nucl Med. 2011 Jun;52(6):886-90
pubmed: 21571796
J Nucl Med. 1997 Dec;38(12):1979-81
pubmed: 9430481
Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):2005-13
pubmed: 21792572
Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73
pubmed: 19995807